To me the importance of today's QIDP is that it validates the B platform for beginning big pharma negotiations. It may be another month or two before there is a license or partner, but the FDA just hit the go button and any fast track and accelerated review that comes out of the impending meeting will just add to the bottom line offers. B-ABSSSI Phase 3 is already a slam dunk, the questions remaining have to do with whether or not the review for the trial will come at the end or as a rolling review. Stay tuned. :-D
Market Data 
Markets 
AI
